SCHEMBL26075595

SCHEMBL26075595

CCOc1cccc(-c2ccc(-c3cc(C)c4cc(C(F)(F)F)ccc4n3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.45
▸ LMNA P02545 4/20 0.44
▸ TP53 P04637 2/20 0.44
▸ RXRA P19793 1/20 0.44
▸ RXRB P28702 1/20 0.44
▸ MAPT P10636 4/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ ACP1 P24666 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ DHODH Q02127 1/20 0.42
▸ THRB P10828 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ SYK P43405 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074055 0.90 LMNA (0.47) LMNATP53MAPTKDM4EMAPK1
SCHEMBL26075379 0.88 PTGS2 (0.44) MAP4K4LMNATP53MAPTNPSR1
SCHEMBL23590329 0.86 KDM4E (0.58) LMNATP53RXRARXRBKDM4E
SCHEMBL26074176 0.83 PLA2G2A (0.53) LMNATP53RXRARXRBMAPT
SCHEMBL26075411 0.81 HMOX1 (0.42) LMNATP53KDM4EACP1HPGD
SCHEMBL26075605 0.81 ACP1 (0.42) LMNATP53MAPTACP1HPGD
SCHEMBL26075601 0.81 AGXT (0.47) LMNAMAPTNPSR1KDM4EACP1
SCHEMBL26075292 0.79 FEN1 (0.41) LMNATP53MAPTKDM4EACP1
SCHEMBL26074059 0.78 LMNA (0.47) LMNATP53RXRARXRBMAPT
SCHEMBL26075586 0.78 HTR2B (0.46) LMNATP53MAPTACP1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD MAP4K4 4780/4885LMNA 1972/4885TP53 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback